Elizabeth Plimack, MD, MS

Moshe C. Ornstein, MD, MA, of Cleveland Clinic says clinicians cannot yet predict which patient with advanced renal cell carcinoma (RCC) will respond better to dual immune checkpoint blockade or to immunotherapy plus a tyrosine kinase inhibitor (TKI), in a discussion moderated by Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center.

Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center opens this CancerNetwork Training Academy discussion on first-line treatment decisions in advanced renal cell carcinoma (RCC) with Terence W. Friedlander, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, and Moshe C. Ornstein, MD, MA, of Cleveland Clinic.